1. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia 
S. Weis, M. Kesselmeier, J.S. Davis, A.M. Morris, S. Lee, A. Scherag, S. Hagel, M.W. Pletz 
Clinical Microbiology and Infection 
Volume 25, Issue 7, Pages (July 2019)
DOI: /j.cmi
Copyright © 2019 The Authors Terms and Conditions

2. Fig. 1
PRISMA flow diagram of study identification and selection process for outcome analysis 431 (modified from Moher and colleagues) [42].
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2019 The Authors Terms and Conditions

3. Fig. 2
Results for the primary and the secondary endpoints in patients with Staphylococcus aureus bacteraemia. ASP, anti-staphylococcal penicillins; CI, confidence interval; RR, relative risk. * Data from propensity matched cohort only.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2019 The Authors Terms and Conditions

4. Fig. 3
Results of the assessment of the impact of a potential inoculum effect in patients with Staphylococcus aureus bacteraemia with endocarditis. ASP, anti-staphylococcal penicillins; CI, confidence interval; RR, relative risk.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2019 The Authors Terms and Conditions

5. Fig. 4
Results of the assessment of the impact of a potential inoculum effect in patients with Staphylococcus aureus bacteraemia with abscesses. ASP, anti-staphylococcal penicillins; CI, confidence interval; RR, relative risk.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2019 The Authors Terms and Conditions